Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Endocrine 1Dermatologic 1Breast 1

Conditions

Melanoma 28Carcinoma, Non-Small-Cell Lung 8Triple Negative Breast Neoplasms 6Carcinoma, Renal Cell 4Pancreatic Neoplasms 3Neoplasm Metastasis 3Skin Neoplasms 2Sarcoma 2Mesothelioma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1

Interventions

spartalizumab 1sargramostim 1dabrafenib 1cobimetinib 1aldesleukin 1Vemurafenib 1PLX8394 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × spartalizumab × Dermatologic × Clear all
NCT02404441 2022-08-03

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Novartis

Phase 1/2 Completed
319 enrolled 41 charts
BreastDermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡